Alchemia wins patents for generic fondaparinux
Wednesday, 25 June, 2008
Alchemia (ASX: ACL) has been granted patents for two of its family of the synthetic heparin oligosaccharides used in its fondaparinux synthesis production method.
Two of its other patent applications have been approved but not yet finalised.
The patents will grant legal protection to Alchemia's method of synthesising fondaparinux sodium up until the year 2022.
Alchemia, and its manufacturing partner Dr Reddy's, hope to go to market in 2009.
Fondaparinux is an anticoagulant medication,generally used subcutaneously daily, particularly in the treatment of deep-vain thrombosis and in those recovering from orthopaedic surgery.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
